NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

I speculate LP/NWBO’s reactivating its LSE OK95 (Ilovetech's position) is a rational, feasible, probable, stealth-compatible and disciplined conclusion (I do not claim that OK95 reactivation has occurred as of yet). Here’s is why:

1. NWBO faces a structural problem that cannot be solved in the U.S.
For more than a decade, NWBO has operated inside a U.S. microstructure environment where:
?dark-pool dominance is extreme
?off-exchange internalization suppresses lit price discovery
?alleged spoofing/layering is under litigation
?synthetic shorting is plausible given the float dynamics-
?OTC venues lack robust surveillance
?enforcement is slow, fragmented, and reactive

The company is currently in litigation against multiple market-making firms, and discovery is underway, creating a high-risk, high-visibility environment where U.S. market makers have every incentive to:
-minimize lit prints
?avoid creating discoverable patterns
?roll synthetic exposure quietly
?suppress volatility
?maintain price containment

The January 2026 dark-pool data, posted by Ilovetech, shows a regime shift consistent with defensive routing behavior. NWBO therefore has a strategic need for a venue that:
?enforces market-abuse rules more aggressively
?does not tolerate spoofing/layering
?provides cleaner price discovery
?breaks single-venue containment
?increases regulatory risk for abusive actors

The London Stock Exchange isn’t just a fit. It’s the only venue with the regulatory teeth and structural leverage capable of breaking the 10+-year long chokehold of spoofing, naked shorting, and synthetic containment that’s suffocated NWBO in the U.S.


2. NWBO already possesses a dormant LSE instrument (0K95) that can be reactivated
This is the key structural fact:
?0K95 was created in 2018
?It remains active in the LSE security master
?It is currently “Reporting Only”
?It is mapped to NWBO’s ISIN
?It is eligible for reactivation
?It requires no new code creation

This gives NWBO a pre-installed conduit into LSE trading by reactivating OK95.
Reactivation is not automatic — but the existence of 0K95 dramatically reduces:
?lead time
?administrative friction
?regulatory complexity
?operational setup
?counterparty awareness

This is the equivalent of having a dormant circuit already wired into the breaker panel.

3. NWBO can prepare the entire reactivation process stealthily
The LSE framework allows quiet preparation of every major step except the final admission.
NWBO could already be doing the following without triggering any public disclosure:

A. Engaging an LSE sponsor (This is private until the prospectus is filed.)
B. Submitting draft documents to the FCA (The FCA allows confidential pre-admission review.)
C. Preparing CREST settlement plumbing (Registrar, settlement agent, and clearing setup can all be done quietly).
D. Coordinating with market makers (MMs can be approached privately to prepare for quoting obligations.)

E. Deciding whether to reuse 0K95 or request a new code (This decision is internal until admission.)

F. Aligning corporate governance with LSE requirements(Board committees, disclosures, and compliance structures can be updated internally.)

G. Timing the move with litigation milestones, NWBO can synchronize the LSE activation with:
?discovery deadlines
?summary-judgment motions
?settlement pressure
?synthetic unwind risk
All of this can be done without leaving a public footprint. Thus, NWBO could be far along in preparation without any visible signal.


4. The strategic payoff of reactivation is enormous
If NWBO activates 0K95 and admits to LSE trading, several powerful forces come into play:

A. FCA + MAR enforcement pressure
The FCA has a strong record of prosecuting:
?spoofing
?layering
?false liquidity
?manipulative order strategies

Replicating U.S. suppression behavior on LSE becomes far riskier.

B. Cross-venue arbitrage breaks containment
Once NWBO trades on both LSE and U.S. OTC:
?arbitrage bots link prices
?LSE price becomes a second anchor
?suppression on one venue becomes harder
?synthetic positions become more expensive to maintain

C. The compliance trap
Market makers face a binary choice If OK95 is reactivated:
?Replicate U.S. behavior on LSE
* high regulatory risk
* cross-border evidence
* potential FCA enforcement
?Dial back behavior on LSE
* more honest price discovery
* upward pressure on the entire complex
Either path increases pressure on synthetic exposure.

D. Litigation leverage increases
If NWBO activates LSE trading:
?defendants’ behavior becomes observable in a stricter jurisdiction
?any manipulation becomes more discoverable
?-settlement pressure increases-
?NWBO gains a forward-looking enforcement mechanism
?-This is the first move NWBO could make that changes the ongoing economics of suppression.

5. The stealth-activation thesis is coherent because the incentives align perfectly
NWBO’s incentives:
?escape U.S. microstructure abuse
?gain a second price-discovery venue
?increase litigation leverage
?force synthetic exposure into the open
?attract institutional capital
?reduce reliance on OTC markets
Market-maker incentives:
?avoid FCA scrutiny
?avoid cross-venue evidence
?avoid triggering synthetic unwind
?avoid lit prints during discovery
Regulatory incentives:
?FCA wants clean markets
?LSE wants more listings
?NWBO wants protection
?The alignment is unusually tight.